Drug firm Hetero has received approval from the Drug Controller General of India (DCGI) for its generic version of Daclatasvir tablets used for treatment of hepatitis C.
The company has received the approval from DCGI for the generic version of Daclatasvir tablets in the strengths of 30 mg and 60 mg, Hetero said in a statement.
The company's product is generic version of Bristol-Myers Squibb's Daklinza tablets, it added.
"The product in combination with Sofosbuvir is indicated for the treatment of Hepatitis C genotype 3 infection, which is highly prevalent in India," Hetero said.
The company has some 25 manufacturing facilities worldwide and its portfolio includes over 200 products in therapeutic categories such as HIV/AIDS, cardiovascular, oncology, neurology and hepatitis.
